Pyxis Oncology, Inc. Basic Shares Outstanding (Weighted Average)
Pyxis Oncology, Inc. (PYXS) reported Basic Shares Outstanding (Weighted Average) of 63.99 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 63.99M shares, a 3.35% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 63.47M shares, a 3.97% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 63.03M shares, a 2.91% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 62.56M shares, a 3.03% increase year-over-year.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 62.14M shares, a 6.33% increase from fiscal 2024.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 58.45M shares, a 46.46% increase from fiscal 2023.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 39.90M shares, a 20.80% increase from fiscal 2022.
- Pyxis Oncology, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 33.03M shares, a 288.93% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 63.99M shares 10-Q · filed 2026-08-13 | 63.70M shares 10-Q · filed 2026-08-13 | 63.50M shares derived: average of 3 quarters · filed 2026-08-13 | 63.26M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 63.47M shares 10-Q · filed 2026-05-14 | 63.25M shares derived: average of 2 quarters · filed 2026-05-14 | 63.02M shares derived: average of 3 quarters · filed 2026-05-14 | 62.74M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 63.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 62.79M shares derived: average of 2 quarters · filed 2026-03-23 | 62.50M shares derived: average of 3 quarters · filed 2026-08-13 | 62.14M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 62.56M shares 10-Q · filed 2025-11-03 | 62.24M shares derived: average of 2 quarters · filed 2026-08-13 | 61.85M shares 10-Q · filed 2025-11-03 | 61.69M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 61.92M shares 10-Q · filed 2026-08-13 | 61.49M shares 10-Q · filed 2026-08-13 | 61.40M shares derived: average of 3 quarters · filed 2026-08-13 | 61.23M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 61.05M shares 10-Q · filed 2026-05-14 | 61.15M shares derived: average of 2 quarters · filed 2026-05-14 | 61.00M shares derived: average of 3 quarters · filed 2026-05-14 | 60.88M shares derived: average of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 61.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 60.98M shares derived: average of 2 quarters · filed 2026-03-23 | 60.82M shares derived: average of 3 quarters · filed 2026-03-23 | 58.45M shares 10-K · filed 2026-03-23 |
| 2024-09-30 | 60.72M shares 10-Q · filed 2025-11-03 | 60.61M shares derived: average of 2 quarters · filed 2025-11-03 | 57.51M shares 10-Q · filed 2025-11-03 | 54.25M shares derived: average of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | 60.50M shares 10-Q · filed 2025-08-14 | 55.89M shares 10-Q · filed 2025-08-14 | 52.09M shares derived: average of 3 quarters · filed 2025-08-14 | 49.40M shares derived: average of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | 51.29M shares 10-Q · filed 2025-05-15 | 47.88M shares derived: average of 2 quarters · filed 2025-05-15 | 45.70M shares derived: average of 3 quarters · filed 2025-05-15 | 43.87M shares derived: average of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 44.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 42.91M shares derived: average of 2 quarters · filed 2025-03-18 | 41.40M shares derived: average of 3 quarters · filed 2025-03-18 | 39.90M shares 10-K · filed 2025-03-18 |
| 2023-09-30 | 41.33M shares 10-Q · filed 2024-11-12 | 39.86M shares derived: average of 2 quarters · filed 2024-11-12 | 38.38M shares 10-Q · filed 2024-11-12 | 37.47M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 38.39M shares 10-Q · filed 2024-08-14 | 36.88M shares 10-Q · filed 2024-08-14 | 36.18M shares derived: average of 3 quarters · filed 2024-08-14 | 35.28M shares derived: average of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | 35.35M shares 10-Q · filed 2024-05-14 | 35.08M shares derived: average of 2 quarters · filed 2024-05-14 | 34.24M shares derived: average of 3 quarters · filed 2024-05-14 | 33.79M shares derived: average of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | 34.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 33.68M shares derived: average of 2 quarters · filed 2024-03-21 | 33.27M shares derived: average of 3 quarters · filed 2024-03-21 | 33.03M shares 10-K · filed 2024-03-21 |
| 2022-09-30 | 32.56M shares 10-Q · filed 2023-11-07 | 32.51M shares derived: average of 2 quarters · filed 2023-11-07 | 32.44M shares 10-Q · filed 2023-11-07 | 31.72M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 32.45M shares 10-Q · filed 2023-08-11 | 32.38M shares 10-Q · filed 2023-08-11 | 31.45M shares derived: average of 3 quarters · filed 2023-08-11 | 23.98M shares derived: average of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | 32.32M shares 10-Q · filed 2023-05-11 | 30.94M shares derived: average of 2 quarters · filed 2023-05-11 | 21.16M shares derived: average of 3 quarters · filed 2023-05-11 | 16.23M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 29.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 15.57M shares derived: average of 2 quarters · filed 2023-03-22 | 10.87M shares derived: average of 3 quarters · filed 2023-03-22 | 8.49M shares 10-K · filed 2023-03-22 |
| 2021-09-30 | 1.58M shares 10-Q · filed 2022-11-01 | 1.53M shares derived: average of 2 quarters · filed 2022-11-01 | 1.47M shares 10-Q · filed 2022-11-01 | |
| 2021-06-30 | 1.47M shares 10-Q · filed 2022-08-15 | 1.41M shares 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |